Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Clinical Trials

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Phase 1

Terminated

Conditions: Metastatic Cancer (Different Solid Tumour Types)

Interventions: Drug: Pazopanib

First Posted Date: 2012-07-17

Last Posted Date: 2018-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 18

Registration Number: NCT01642017

Locations: 🇫🇷
Hôpital Saint André, Bordeaux, France
🇫🇷
Centre François BACLESSE, Caen, France
🇫🇷
Institut Claudius REGAUD, Toulouse, France

and more 1 locations

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Phase 1

Completed

Conditions: Malignant Neoplasm of Gastrointestinal Tract
Genitourinary Neoplasms Malignancy and Gender Unspecified
Head and Neck Neoplasms
Melanoma
Malignant Neoplasm of Thorax
Malignant Neoplasm of Breast
CNS Malignancy

Interventions: Drug: Alisertib
Drug: Pazopanib

First Posted Date: 2012-07-13

Last Posted Date: 2019-07-22

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 28

Registration Number: NCT01639911

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Not Applicable

Completed

Conditions: Advanced Solid Tumors
Cancer

Interventions: Drug: Sunitinib
Drug: Sorafenib
Drug: Erlotinib
Drug: Everolimus
Drug: Lapatinib
Drug: Dasatinib
Drug: Pazopanib
Drug: Vemurafenib
Procedure: tumor biopsy
Procedure: skin biopsy (optional)

First Posted Date: 2012-07-10

Last Posted Date: 2021-04-15

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 43

Registration Number: NCT01636908

Locations: 🇳🇱
VUMedical Center, Amsterdam, Netherlands

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Gemcitabine
Drug: Pazopanib

First Posted Date: 2012-06-19

Last Posted Date: 2017-08-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT01622660

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Drug: Gemcitabine
Drug: pazopanib

First Posted Date: 2012-06-01

Last Posted Date: 2021-02-25

Lead Sponsor: Linda R Duska

Target Recruit Count: 148

Registration Number: NCT01610206

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Maine Medical Center (MMP Women's Health), Scarborough, Maine, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 5 locations

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Neoplasm

Interventions: Drug: Pazopanib and paclitaxel

First Posted Date: 2012-05-30

Last Posted Date: 2017-03-10

Lead Sponsor: Imperial College London

Target Recruit Count: 16

Registration Number: NCT01608009

Locations: 🇬🇧
Southend University Hospital NHS Foundation Trust, Southend, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Phase 1

Conditions: Ovarian Cancer

Interventions: Drug: pazopanib in combination with weekly topotecan

First Posted Date: 2012-05-17

Last Posted Date: 2016-10-11

Lead Sponsor: JSehouli

Target Recruit Count: 68

Registration Number: NCT01600573

Locations: 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

Not Applicable

Terminated

Conditions: Stage IV Renal Cell Cancer
Recurrent Renal Cell Cancer
Clear Cell Renal Cell Carcinoma

Interventions: Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Other: pharmacogenomic studies

First Posted Date: 2012-05-16

Last Posted Date: 2017-06-08

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT01599832

Locations: 🇺🇸
Illinois Cancer Care (Peoria), Peoria, Illinois, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 1 locations

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

Phase 2

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2012-04-16

Last Posted Date: 2014-03-12

Lead Sponsor: Associació per a la Recerca Oncologica, Spain

Target Recruit Count: 27

Registration Number: NCT01577784

Locations: 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain

and more 7 locations

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Phase 3

Active, not recruiting

Conditions: Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7

Interventions: Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Placebo Administration
Drug: Pazopanib Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2012-04-11

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 129

Registration Number: NCT01575548

Locations: 🇺🇸
Cancer Center of Kansas - Salina, Salina, Kansas, United States
🇺🇸
Salina Regional Health Center, Salina, Kansas, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

and more 581 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy